JeanMarie Guenot is a successful woman who has built a remarkable career. At the moment, she is recognized as one of the women who have made a difference in the pharmaceutical and biotechnology industry. Some of her significant achievements include the development and discovery of several drugs, negotiating merger &acquisition and building various successful companies.
Guenot went for her Ph.D. education at the University of California where she studied physical and medicinal chemistry. After completing the degree, Guenot was to venture into her career, specializing in X-ray refinement, drug design and predicting protein structure.
The successful businesswoman started her professional career by working at the Atlas Venture where she was in charge of managing capital investments and also building life science companies. The scientist, later on, went to practice at the Hoffmann-La Roche where she was responsible for preclinical research and several other responsibilities.
At the moment, Guenot is the chief executive officer of Amphivena Therapeutics. The biotechnology company has been doing very well under her leadership. Not long ago, Guenot announced to the world that the great Food and Drug Administration Agency had finally accepted the application from Amphivena Therapeutics to commence an investigative trial in one of the drugs that help in the fight against cancer. The drug, known as AMV564 is manufactured by the pharmaceutical company, and it will work with several other antibodies to achieve its objective.
According to JeanMarie Guenot, the first stage of the drug trial will study the safety level of increasing the dosage of the medicine in cancer patients. The experts will examine the data vigorously and determine its effectiveness in curing tumors and preventing others from occurring. Jean and her team will work hard to ensure that the drug is safe for the individuals suffering from the dangerous disease.
Amphivena Therapeutics was established several years ago. Under the leadership of JeanMarie Guenot, the pharmaceutical company has achieved a lot. In the recent times, the company has been working hard to introduce better and innovative ways of dealing with cancer. The news to start the trial is a good sign for the enterprise. It is also an indication that Jean has not wasted her Ph.D., and her efforts are bearing fruit.